Recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants.: HP40-308/2022E-PDF
"The objective of this advisory committee statement is to review evidence and develop guidance on strategies to prevent severe consequences of Respiratory syncytial virus (RSV) infection in children at high risk of severe RSV disease by administration of monoclonal antibody"--Guidance objective, page 8.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.910768&sl=0
Department/Agency | Canada. National Advisory Committee on Immunization, issuing body. |
---|---|
Title | Recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants. |
Publication type | Monograph |
Language | [English] |
Other language editions | [French] |
Later edition | Recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants. |
Format | Electronic |
Electronic document | |
Note(s) | Cover title. "Publication date: June 2022." "Protecting and empowering Canadians to improve their health." At head of title: An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI). Issued also in French under title: Utilisation recommandée du palivizumab pour réduire les complications de l'infection par le virus respiratoire syncytial chez les nourrissons. Includes bibliographical references (pages 76-97). |
Publishing information | [Ottawa] : Public Health Agency of Canada = Agence de la santé publique du Canada, 2022. ©2022 |
Description | 1 online resource (151 pages) |
ISBN | 9780660433523 |
Catalogue number |
|
Departmental catalogue number | 220087 |
Subject terms | Palivizumab -- Canada. Respiratory syncytial virus -- Canada. Infants -- Diseases -- Canada. |
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.- Date modified: